Company news

TriSalus Life Sciences, Inc. news in 2025

TriSalus Life Sciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

December 4, 2025

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

November 18, 2025

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

November 13, 2025

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

November 11, 2025

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

November 10, 2025

TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

October 30, 2025

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

August 28, 2025

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

August 12, 2025

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

August 11, 2025

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

July 29, 2025

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

July 24, 2025

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

June 23, 2025

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

June 4, 2025

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 30, 2025

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 15, 2025

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

May 12, 2025

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

April 30, 2025

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

March 27, 2025

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

March 26, 2025

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

March 6, 2025

TriSalus Life Sciences Announces Key Appointments to Board of Directors

February 2, 2025

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

February 2, 2025

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

January 22, 2025

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

January 8, 2025

TriSalus Announces Leadership Changes

January 7, 2025

Calls in 2025

Decks in 2025